“Lumpy” licensing lag hits AFT profits

Kiwi pharmaco behind Maxigesic sees net profits down 2/3 year-on-year but leadership remains upbeat about the future Lower licencing income and increased growth in spending were factors which saw the AFT Pharmaceuticals’ first-half net profits down two-thirds year on the same period last year, the company’s annual report shows.   But management remained bullish with